1. bookTom 49 (2015): Zeszyt 2 (June 2015)
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
1581-3207
Pierwsze wydanie
30 Apr 2007
Częstotliwość wydawania
4 razy w roku
Języki
Angielski
Otwarty dostęp

The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement

Data publikacji: 25 Mar 2015
Tom & Zeszyt: Tom 49 (2015) - Zeszyt 2 (June 2015)
Zakres stron: 200 - 208
Otrzymano: 14 Aug 2014
Przyjęty: 02 Oct 2014
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
1581-3207
Pierwsze wydanie
30 Apr 2007
Częstotliwość wydawania
4 razy w roku
Języki
Angielski

1. Zakelj MP, Zadnik V, Zagar T, Zakotnik B. Survival of cancer patients, diagnosed in 1991-2005 in Slovenia. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2009. p. 229.Search in Google Scholar

2. Treglia G, Taralli S, Salsano M, Muoio B, Sadeghi R, Giovanella L. Prevalence and malignancy risk of focal colorectal incidental uptake detected by 18F-FDG-PET or PET/CT: a meta-analysis. Radiol Oncol 2015; 49(2): 200-208.; 48: 99-104.10.2478/raon-2013-0035Search in Google Scholar

3. Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8.10.2478/v10019-009-0004-1Search in Google Scholar

4. Ocvirk J, Heeger S, McCloud P, Hofheinz RD. A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis. Radiol Oncol 2013; 47: 166-75.10.2478/raon-2013-0014Search in Google Scholar

5. Reeder CE, Gordon D. Managing oncology costs. Am J Manag Care., 2006; 12: 3-16.Search in Google Scholar

6. Van Cutsem EJD, Oliveira J. On behalf of the ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19(Suppl 2): ii33-4.10.1093/annonc/mdn079Search in Google Scholar

7. Mesti T. [The cost of systemic therapy for metastatic colorectal carcinoma at Institute of Oncology Ljubljana in the year 2009]. Master’s thesis. [Slovenian]. University of Ljubljana, Faculty of Economics; 2011. Available at: http://www.cek.ef.uni-lj.si/magister/mesti4363.pdfSearch in Google Scholar

8. Song X, Zhao Z, Barber B, Gregory C, Zhun C, Sue G. Cost of illness in patients with metastatic colorectal cancer. J Med Econ 2011; 14: 1-9.10.3111/13696998.2010.536870Search in Google Scholar

9. Ferro SA, Myer BS, Wolff DA, Poniewierski MS, Culakova E, Cosler LE, et al. Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care 2008; 14: 717-25.Search in Google Scholar

10. Paramore LC, Thomas SK, Knopf KB. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer, 2006; 6: 52-8.10.3816/CCC.2006.n.021Search in Google Scholar

11. Bending WM, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J, et al. Estimating the direct costs of bowel cancer services provided by the National Health Service. Int J Technol Assess Health Care 2010; 26: 362-9.10.1017/S0266462310001078Search in Google Scholar

12. Piškur P, Sonc M, Čufer T, Borštnar S, Mrhar A. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: A Slovenian perspective. Anticancer Drugs, 2006; 17: 719-24.10.1097/01.cad.0000215057.47695.dbSearch in Google Scholar

13. Obradovič M, Mrhar A, Kos M. Cost effectiveness of UGT1A1 genotypes in second line, high dose, once every three week irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics 2008; 9: 539-49.10.2217/14622416.9.5.539Search in Google Scholar

14. Organisation for Economic Cooperation and Development. Health data. 2008, May. Available from: http://www.oecd-ilibrary.org/economics/country-statistical-profile-slovenia_20752288-table-svn. Accessed 10 August 2011.Search in Google Scholar

15. Marušič D, Ceglar J, Prevolnik-Rupel V. [Reimbursement of health care services with special attention paid to drg reimbursement system in Slovenia]. [Slovenian]. Zdrav Varst 2009; 48: 177-83.Search in Google Scholar

16. Busse R. Moving from passive to active provider payment systems: DRGbased financing. International conference markets in European health systems: opportunities, challenges and limitations; 2009. Available from: http://www.cef-see.org/health/#. Accessed 20 May 2009.Search in Google Scholar

17. Stariha J. [The adequacy of funding for acute hospital treatment after a system comparable groups of cases.] [Slovenian]. Master’s thesis. University of Primorska, Faculty of Management; 2009. Available at: http://www.ediplome.fm-kp.si/Stariha_Jurij_20091028.pdf. Accessed 10 August 2010.Search in Google Scholar

18. Zupanc I. [DRG: questions and answers about the classification system and the financing of hospitals.][Slovenian].Ljubljana: Inštitut za varovanje zdravja RS; 2008.Search in Google Scholar

19. Tekavčič M. [Cost management]. [Slovenian]. Ljubljana : Gospodarski vestnik, ISBN/ISSN: 867061149X; 1997.Search in Google Scholar

20. Grandlich C. Using activity-based costing in surgery. AORN J, 2004; 79: 18-192.10.1016/S0001-2092(06)61152-6Search in Google Scholar

Polecane artykuły z Trend MD

Zaplanuj zdalną konferencję ze Sciendo